Opinion|Videos|November 29, 2023
Clinical Pearls on the Treatment of Metastatic and Unresectable Melanoma
Author(s)Hussein A. Tawbi, MD, PhD
Hussein Tawbi, MD, PhD, closes his discussion by sharing some clinical pearls for fellow oncologists treating patients with metastatic melanoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
Neoadjuvant Botensilimab/Balstilimab Shows Activity in Colon Cancer
5